Tolectin

Rheumatoid Arthritis, Arthritis, Juvenile, Ankylosing Spondylitis + 1 more
Treatment
20 Active Studies for Tolectin

What is Tolectin

TolmetinThe Generic name of this drug
Treatment SummaryIbuprofen is a type of non-steroidal anti-inflammatory drug (NSAID) that works in the same way as indomethacin to reduce inflammation and pain.
Tolmetin Sodiumis the brand name
image of different drug pills on a surface
Tolectin Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Tolmetin Sodium
Tolmetin
1991
9

Effectiveness

How Tolectin Affects PatientsTolmetin is a type of medicine used to reduce inflammation, pain, and fever. It has been studied in animals and found to be effective in preventing arthritis and relieving inflammation. In people, tolmetin has been found to be just as effective as aspirin or indomethacin in treating conditions like rheumatoid arthritis and osteoarthritis, but with fewer side effects. Additionally, when taken in combination with other treatments like gold salts or corticosteroids, tolmetin has been found to provide additional therapeutic benefits. Unfortunately, taking tolmetin with salicylates is not recommended,
How Tolectin works in the bodyWe don't know exactly how tolmetin works. Tests in animals and humans show it reduces inflammation by stopping the production of prostaglandins. This reduction may be responsible for its anti-inflammatory effect. Tolmetin does not seem to change the course of the underlying disease.

When to interrupt dosage

The proposed measure of Tolectin is contingent on the recognized affliction, including Rheumatoid Arthritis, Ankylosing Spondylitis and Rheumatoid Arthritis, Juvenile. The dosage shifts, in light of the method of delivery (e.g. Oral or Tablet) displayed in the table beneath.
Condition
Dosage
Administration
Rheumatoid Arthritis
, 600.0 mg, 400.0 mg, 200.0 mg, 245.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet - Oral, Tablet
Ankylosing Spondylitis
, 600.0 mg, 400.0 mg, 200.0 mg, 245.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet - Oral, Tablet
Arthritis, Juvenile
, 600.0 mg, 400.0 mg, 200.0 mg, 245.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet - Oral, Tablet
Osteoarthritis
, 600.0 mg, 400.0 mg, 200.0 mg, 245.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet - Oral, Tablet

Warnings

Tolectin has two contraindications and should not be administered in tandem with the conditions indicated in the following table.Tolectin Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
Pain
Do Not Combine
There are 20 known major drug interactions with Tolectin.
Common Tolectin Drug Interactions
Drug Name
Risk Level
Description
Macimorelin
Major
The therapeutic efficacy of Macimorelin can be decreased when used in combination with Tolmetin.
Methotrexate
Major
The serum concentration of Methotrexate can be increased when it is combined with Tolmetin.
Mifamurtide
Major
The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Tolmetin.
Neomycin
Major
The risk or severity of nephrotoxicity can be increased when Tolmetin is combined with Neomycin.
Omacetaxine mepesuccinate
Major
The risk or severity of bleeding can be increased when Tolmetin is combined with Omacetaxine mepesuccinate.
Tolectin Toxicity & Overdose RiskOverdosing on a drug may cause tiredness, sleepiness, nausea, vomiting, and stomach pain.

Tolectin Novel Uses: Which Conditions Have a Clinical Trial Featuring Tolectin?

80 active clinical trials are currently analyzing the capacity of Tolectin to alleviate Rheumatoid Arthritis, Juvenile Osteoarthritis and Rheumatoid Arthritis.
Condition
Clinical Trials
Trial Phases
Ankylosing Spondylitis
3 Actively Recruiting
Phase 3, Not Applicable
Osteoarthritis
0 Actively Recruiting
Arthritis, Juvenile
1 Actively Recruiting
Not Applicable
Rheumatoid Arthritis
53 Actively Recruiting
Not Applicable, Phase 4, Phase 3, Phase 2, Phase 1

Tolectin Reviews: What are patients saying about Tolectin?

1Patient Review
3/1/2010
Tolectin for Joint Damage causing Pain and Loss of Function
I had a serious allergic reaction to this that landed me in the hospital. Hives, swelling, blackout, and vomiting were all symptoms I experienced.
1Patient Review
8/13/2020
Tolectin for Joint Damage causing Pain and Loss of Function
After taking this drug, I had a deep and restful sleep.
1Patient Review
3/1/2010
Tolectin for Joint Damage causing Pain and Loss of Function
I had an incredibly severe allergic reaction to this that landed me in the hospital. If you have any allergies, PLEASE stay away from this.
1Patient Review
8/13/2020
Tolectin for Joint Damage causing Pain and Loss of Function
I took this drug and it made me so sleepy that I could barely keep my eyes open.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about tolectin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is tolectin still available?

"The Tolectin 600 brand name will no longer be available in the U.S. Generic versions of this product that have been approved by the FDA may be available as alternatives."

Answered by AI

What is tolectin used for?

"Tolmetin is an anti-inflammatory drug used to treat mild to moderate pain and help relieve symptoms of arthritis, such as inflammation, swelling, stiffness, and joint pain."

Answered by AI

What was Vioxx used for?

"What is Vioxx?

Vioxx is a medication used to relieve pain. It belongs to a class of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). Vioxx is a COX-2 selective NSAID, which means it works by specifically targeting an enzyme known to cause pain and inflammation. Vioxx is related to other NSAIDs such as ibuprofen and naproxen, but it is more selective in its actions. Vioxx is a prescription medication used to relieve arthritis pain, acute pain in adults, and painful menstrual cycles."

Answered by AI

Clinical Trials for Tolectin

Image of Sunnybrook Health Sciences Centre in Toronto, Canada.

Steroids for Rheumatoid Arthritis

18+
All Sexes
Toronto, Canada
People living with rheumatoid arthritis (RA) often experience flares-periods where their symptoms suddenly get worse. These flares can cause significant pain, make it harder to move and do daily activities, and lower overall quality of life. Doctors often treat flares with medications called glucocorticoids (GCs), which reduce inflammation. These medications can be taken by mouth (oral/PO) or given as a single injection into the muscle (intramuscular/IM). However, it's not clear which option works better from the patient's point of view-especially when it comes to relief of symptoms, improvements in function, and satisfaction with treatment. Most research so far has focused on how well the drugs control the disease, rather than how they impact the patient's overall experience. Our Research Questions: 1. Does a single GC injection work just as well as taking pills over a few weeks in improving symptoms reported by patients? 2. How do the two treatments compare in terms of symptom relief, ability to function, and patient satisfaction? 3. What do patients think and feel about using GCs to treat RA flares? What We Think: We believe that a one-time GC injection is just as good as taking pills for a few weeks when it comes to managing RA flares. In fact, the injection might even be safer and preferred by patients. What We're Doing: We will study 220 adults with RA who are currently having a flare (with at least 3 swollen and tender joints). These patients will be recruited from rheumatology clinics at the University of Toronto and must not have used GCs in the past month. They will be randomly assigned to receive either: A single injection (Methylprednisolone 120 mg), or Oral pills (Prednisone starting at 15 mg daily and tapering down over 3 weeks). The main thing we'll look at is how much better patients feel after 6 weeks, based on a questionnaire designed to measure RA flares. We'll also look at how well they function, how satisfied they are with the treatment, and whether they had any side effects. In addition, 20 patients (10 from each group) will be interviewed to understand their experiences and opinions about flare treatment in more detail. Why This Is Possible: We've already surveyed University of Toronto rheumatologists who support the idea and provided input on study design. We've also partnered with experts in research methods, national arthritis organizations, and patient groups to make sure the study is relevant and meaningful. Ethics approval has been obtained. Why It Matters: RA flares can have a major impact on people's lives. While current treatments help control inflammation, we need to better understand how these treatments affect people from their own perspective. This study will shift the focus to what matters most to patients, helping doctors and patients choose the best treatment based not only on medical results but also on the patient's experience. This could lead to more effective and personalized care for people living with RA.
Phase 4
Waitlist Available
Sunnybrook Health Sciences Centre (+4 Sites)
Image of California Clinical Trials Medical Group in Glendale, United States.

NTR-1011 for Lupus and Rheumatoid Arthritis

18 - 75
All Sexes
Glendale, CA
This phase 1a and 1b study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy of NTR-1011 in healthy adults and in adult patients with systemic lupus erythematosus and rheumatoid arthritis. The main goals of this study are to determine the safety profile of NTR-1011 across subcutaneous and intravenous dose levels, understand how the drug behaves in the body, characterize its biological activity through relevant pharmacodynamic markers, assess the potential for immune responses to treatment, and explore early signals of clinical benefit in autoimmune disease settings. This is a randomized, double blind, placebo controlled study that begins with a single ascending dose evaluation in healthy volunteers followed by a multiple dose assessment in patients. The design is intended to define the highest safe and well tolerated dose, establish a robust PK and PD baseline, and generate initial patient level evidence to support dose selection and advancement into subsequent clinical development.
Phase 1
Recruiting
California Clinical Trials Medical GroupHakop Gevorkyan, MDNeutrolis
Image of Weill Cornell Medical College in New York, United States.

Health Coaching for Rheumatoid Arthritis

18+
All Sexes
New York, NY
The goal of this clinical trial is to learn if peer coaching works to reduce levels of anxiety and/or depression in adults diagnosed with Rheumatoid Arthritis (RA). The main questions it aims to answer are: Do people with RA who complete the intervention with a peer coach have lower levels of anxiety and/or depression at 6 months from baseline? Do people with RA who complete the intervention with a peer coach have lower levels of anxiety and/or depression at 6 months compared to those in the control arm? Researchers will compare the peer coaching intervention to an active-control arm (where people without RA coach participants on general health and nutrition topics) to see if peer coaching works to reduce anxiety and/or depression. Participants will meet with a coach every week for 9 weeks and complete several surveys before, during and after the intervention
Recruiting
Has No Placebo
Weill Cornell Medical CollegeIris Y Navarro-Millán, MDBristol-Myers Squibb
Image of Humana Healthcare Research, Inc. in Louisville, United States.

Academic Detailing for Rheumatoid Arthritis

Any Age
All Sexes
Louisville, KY
The goal of this trial is to learn if an interactive evidence-based educational outreach visits to clinicians who prescribe biologics change prescribing of biosimilar medications. The main questions it aims to answer are: 1. Do educational outreach visits lead to a higher number of prescriptions for biosimilar versions of adalimumab? 2. Do in-person or virtual visits work better? Researchers will compare clinicians offered the educational outreach visit to those who are not offered the visit to see if there is a difference in prescribing of biosimilar versions of adalimumab instead of the original brand-name version. Participants will be offered the chance to meet with a trained clinician who will provide educational information tailored to their knowledge and attitudes on the topic. They will also be provided an educational brochure and patient educational materials.
Waitlist Available
Has No Placebo
Humana Healthcare Research, Inc. (+1 Sites)
Have you considered Tolectin clinical trials? We made a collection of clinical trials featuring Tolectin, we think they might fit your search criteria.Go to Trials
Image of University of Minnesota Medical School, Division of Rheumatic and Autoimmune Diseases in Minneapolis, United States.

Ultrasound Therapy for Rheumatoid Arthritis

18+
All Sexes
Minneapolis, MN
The At-Home ULTRA Study will evaluate performance of the MINI system as indicated for the treatment of adults with active, moderate to severe rheumatoid arthritis who are inadequate responders or are intolerant to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), biologic DMARDs (bDMARDs), or targeted synthetic DMARDs (tsDMARDs). The non-invasive study device delivers ultrasound stimulation to the spleen to reduce inflammation. The study will enroll at least 60 participants at up to 8 sites. There will be three arms consisting of two active stimulation groups (treatment) and one non-active stimulation group (sham-control). After completing the double-blinded primary endpoint assessment period at Week 12, there will be a one-way crossover of control participants to active stimulation and an additional 12 week follow-up with all participants to evaluate long-term outcomes.
Recruiting
Drug
University of Minnesota Medical School, Division of Rheumatic and Autoimmune DiseasesHubert LimSecondWave Systems Inc.
Image of St. Lawrence Health in Potsdam, United States.

Primary Care for Rheumatoid Arthritis

18+
All Sexes
Potsdam, NY
Rheumatoid arthritis (RA) is a complex autoimmune disease where the immune system attacks healthy joint tissue; causing pain, swelling, and stiffness of the joints. This disease effects lots of people in the US and can lead to major joint damage if not properly treated. In rural areas like northern NY, these are underserved areas for RA patients, thus many patients struggle to get the appropriate care. This model is testing whether primary care providers (PCP) can safely and effectively provide stable RA patients with the proper treatment rather than send them to a specialist. PCPs were trained through classes, case reviews, and a final exam. Patients will be randomly assigned to either see a trained PCP or their normal rheumatologist at the rheumatology clinic. This study will examine how patients are doing over a year using medical exams and patient feedback. If this model proves to be successful, it will make RA treatment easier and more affordable for patients.
Recruiting
Has No Placebo
St. Lawrence HealthEyal Kedar, MD
Have you considered Tolectin clinical trials? We made a collection of clinical trials featuring Tolectin, we think they might fit your search criteria.Go to Trials
Image of Clinical Research Of West Florida - Phase I Unit /ID# 272428 in Clearwater, United States.

Targeted Therapies for Rheumatoid Arthritis

18+
All Sexes
Clearwater, FL
Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will evaluate the efficacy and safety of targeted therapies through a series of substudies for the treatment of moderately to severely active Rheumatoid Arthritis (RA). This study currently includes 3 substudies evaluating different treatments in participants with RA. Substudy 1 will evaluate lutikizumab monotherapy (treatment given alone) compared to placebo (looks like the study treatment but contains no medicine). Substudy 2 will evaluate ravagalimab monotherapy compared to placebo and Substudy 3 will evaluate lutikizumab and ravagalimab combination therapy (treatments given together) compared to placebo. Approximately 180 participants who have failed 1 or 2 biologic/targeted synthetic disease-modifying antirheumatic drug (tsDMARD) therapies will be enrolled in the study at approximately 65 sites worldwide. There may be higher treatment burden for participants in this trial compared to their standard of care treatment without participating in this study. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Phase 2
Recruiting
Clinical Research Of West Florida - Phase I Unit /ID# 272428 (+30 Sites)ABBVIE INC.AbbVie
Have you considered Tolectin clinical trials? We made a collection of clinical trials featuring Tolectin, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security